Skip to main content
Industry News
Investigative CAR T-cell therapy targets CXCR5 protein

A novel chimeric antigen receptor T-cell therapy was developed by researchers in Germany and has been studied in preclinical tests as a potential treatment for chronic lymphocytic leukemia and follicular lymphomas, according to research in the journal Nature Communications. The approach sensitizes T cells to the B-cell homing protein CXCR5, which plays a role in B cells' movement from the bone marrow to organs such as lymph nodes and the spleen.

Full Story: